New and investigational treatments in cystic fibrosis

Therapeutic Advances in Respiratory Disease

Volumn 5, Issue 4, 2011, Pages 275-282

  Narasimhan, Mangala ^a   Cohen, Rubin ^a  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

Author keywords

cystic fibrosis; gene therapy; protein modifiers

Indexed keywords

AEROQUIN; AMIKACIN; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; ARIKACE; ATALUREN; AZITHROMYCIN; AZTREONAM; AZTREONAM LYSINE; CIPROFLOXACIN; COLISTIN; DENUFOSOL; DORNASE ALFA; FOSFOMYCIN; IVACAFTOR; LANCOVUTIDE; LEVOFLOXACIN; MACROLIDE; MANNITOL; MP 376; PLACEBO; PS 552; TOBRAMYCIN; UNCLASSIFIED DRUG;

CONJUNCTIVITIS; CYSTIC FIBROSIS; DEVICE; DISEASE EXACERBATION; FOOD AND DRUG ADMINISTRATION; FORCED EXPIRATORY VOLUME; GENE EXPRESSION; HOSPITALIZATION; HUMAN; HYDRATOR; LARYNGITIS; NEBULIZER; PHARYNGITIS; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; REVIEW; SIDE EFFECT; THORAX PAIN; VOICE CHANGE;

ADMINISTRATION, INHALATION; AEROSOLS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; CYSTIC FIBROSIS; HUMANS;

EID: 79960150961     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753465811398267     Document Type: Review

References (38)

1. Accurso F.J. Rowe S.M. Clancy J.P. Boyle M.P. Dunitz J.M. Durie P.R. (2010) Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 363: 1991–2003.
2. Aziz I. Kastelik J.A. (2006) Hypertonic saline for cystic fibrosis. N Engl J Med 354: 1848–1850.
3. Balfour-Lynn I.M. (2007) Anti-inflammatory approaches to cystic fibrosis airways disease. Curr Opin Pulm Med 13: 522–528.
4. Bilton D. Robinson P. Cooper P. Gallagher C. Kolbe J. Charlton B. (2010) Phase III study of inhaled dry powder mannitol (Bronchitol™) in cystic fibrosis ’ results from the 6 month open label phase. Am J Respir Crit Care Med 181: A2338–A2338. [abstract].
5. Binder H.J. (2006) Causes of chronic diarrhea. N Engl J Med 355: 236–239.
6. Cystic Fibrosis Foundation. (2002) Cystic Fibrosis Foundation patient registry. 2001 Annual data report to the center directors, Bethesda, MD: Cystic Fibrosis Foundation.
7. Daviskas E. Anderson S.D. Jaques A. Charlton B. (2010) Inhaled mannitol improves the hydration and surface properties of sputum in patients with cystic fibrosis. Chest 137: 861–868.
8. Donaldson S.H. (2008) Hydrator therapies for cystic fibrosis in lung disease. Ped Pulm 43: S18's23.
9. Donaldson S.H. Bennet W.D. Zeman K.L. Knowles M.R. Tarran R. Boucher R.C. (2006) Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 354: 241–250.
10. Drumm M.L. Konstan M.W. Schluchter M.D. Handler A. Pace R. Zou F. (2005) Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med 353: 1443–1453.
11. Elkins M.R. Robinson M. Rose B.R. Harbour C. Moriarty C.P. Marks G.B. (2006) A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 354: 229–240.
12. Geller D.E. (2008) The science of aerosol delivery in cystic fibrosis. Ped Pulm 43: S5's17.
13. Geller D.E. Pitlick W.H. Nardella P.A. Tracewell W.G. Ramsey B.W. (2002) Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 122: 219–226.
14. Gibson R.L. Burns J.L. Ramsey B.W. (2003) State of the art: pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 168: 918–951.
15. Henry R.L. Mellis C.M. Petrovic L. (1992) Mucoid pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Ped Pulm 12: 158–161.
16. Hodson M.E. Gallagher C.G. Govan J.R. (2002) A randomized clinical trial of nebulized tobramycin or colistin in cystic fibrosis. Eur Respir J 20: 658–664.
17. Immundo L. Barasch J. Prince A. Al-Awquit Q. (1995) Cystic fibrosis epithelial cells have a receptor for pathogenic bacteria on their apical surface. Proc Natl Acad Sci U S A 92: 3019–3023.
18. Jaques A. Daviskas E. Turton J.A. (2008) Inhaled mannitol improves lung function in cystic fibrosis. Chest 133: 1388–1396.
19. Jensen T. Pedersen S.S. Garne S. Heilmann C. Hoiby N. Koch C. (1987) Colistin inhalation therapy in cystic fibrosis patients with chronic pseudomonas aeruginosa lung infection. J Antimicrob Chemother 19: 831–838.
20. Kerem E. Hirawat S. Armoni S. Yaakov Y. Shoseyou D. Cohen M. (2008) Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 372: 719–727.
21. King M. Dasgupta B. Tomkiewcz R.P. Brown N. (1997) Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease. Am J Respir Crit Care Med 156: 173–177.
22. Labro M.T. (1998) Anti-inflammatory activity of macrolides: a new therapeutic potential?. J Antimicrob Chemother 41: 37–46.
23. Laube B.L. Auci R.M. Shields D.E. Christiansen D.H. Lucas M.K. Fuchs H.J. (1996) Effect of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis. Am J Respir Crit Care Med 153: 752–760.
24. MacLeod D.L. Barker L.M. Sutherland J.L. Moss S.C. Gurgel J.L. Kenney T.F. (2009) Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis. J Antimicrob Chemother 64: 829–836.
25. Minasian C. Wallis C. Metcalfe C. Bush A. (2010) Comparison of inhaled mannitol, daily rhDNase and a combination of both in children with cystic fibrosis: a randomized trial. Thorax 65: 51–56.
26. Minic P. Fustic S. Solyom E. (2010) A multi-cycle open label study of nebulized liposomal amikacin (Arikace™) in the treatment of cystic fibrosis patients with chronic pseudomonas aeruginosa lung infection. Ped Pulm 45: S33's33.
27. Moss R.B. Schaberg A. Tian W. Xue X. Ramsey B. Accurso F.J. (2010) Denufosol improved lung function and was well tolerated in adolescents with cystic fibrosis. Ped Pulm 45: S33's33.
28. Ramsey B.W. Pepe M.S. Quan J.M. Otto K.L. Montgomery B. Williams-Warren J. (1999) Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 340: 23–30.
29. Retsch-Bogart G.Z. Quittner A.L. Gibson R.L. Oermann C.M. Mc Coy K.S. Montgomery A.B. (2009) Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 135: 1223–1232.
30. Rowe S.M. Clancy J.P. (2006) Advances in cystic fibrosis therapies. Curr Opin Pediatr 18: 604–613.
31. Rowe S.M. Miller S. Sorscher E.J. (2005) Mechanisms of disease: cystic fibrosis. N Engl J Med 352: 1992–2001.
32. Saiman L. Anstead M. Mayer-Hamblett N. Lands L.C. Kloster M. Hocevar-Trnka J. (2010) Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa. JAMA 303: 1707–1715.
33. Saiman L. Marshall B.C. Mayer-Hamblett N. Burns J.L. Quittner A.L. Cibene D.A. (2003) The macrolide study group: a multicenter, randomized, placebo controlled, double-blind trial of azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. JAMA 290: 1749–1756.
34. Suri R. Metcalfe C. Lees B. Grieve R. Flather M. DPhil C.N. (2001) Comparison of hypertonic saline and alternate-day or daily recombinant deoxyribonuclease in children with cystic fibrosis: a randomized trial. Lancet 358: 1316–1321.
35. Van Goor F. Straley K.S. Cao D. Gonzalez J. Hadida S. Hazlewood A. (2006) Rescue of delta F508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 290: L1117–L1130.
36. Wills P.J. (2007) Inhaled mannitol in cystic fibrosis. Expert Opin Investig Drugs 16: 1121–1126.
37. Yankaskas J.R. Marshall B.C. Sufian B. Simon R.H. Rodman D. (2004) Cystic fibrosis adult care: consensus conference report. Chest 125: 1–39.
38. Zeitlin P.L. (2007) Emerging drug treatments for cystic fibrosis. Expert Opin Emerging Drugs 12: 329–336.